This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Landis-Piwowar, K. R. Articles by Dou, Q. P. Search for Related Content PubMed PubMed Citation Articles by Landis-Piwowar, K. R. Articles by Dou, Q. P.

A Novel Prodrug of the Green Tea Polyphenol (–)-Epigallocatechin-3-Gallate as a Potential Anticancer Agent

¹ The Prevention Program, Barbara Ann Karmanos Cancer Institute, and Department of Pathology, School of Medicine, Wayne State University, Detroit, Michigan; ² Department of Applied Biology and Chemical Technology and the Institute of Molecular Technology for Drug Discovery and Synthesis, the Hong Kong Polytechnic University, Hong Kong SAR, China; and ³ School of Applied Science, University of Science and Technology Beijing, Beijing, PR China

Requests for reprints: Q. Ping Dou, The Prevention Program, Barbara Ann Karmanos Cancer Institute, and Department of Pathology, School of Medicine, Wayne State University, 640.1 HWCRC, 4100 John R Road, Detroit, MI 48201. Phone: 313-576-8301; Fax: 313-576-8307; E-mail: doup{at}karmanos.org.

The most abundant and biologically active green tea catechin, (–)-epigallocatechin-3-gallate or (–)-EGCG, has been shown to act as a proteasome inhibitor and tumor cell death inducer. However, (–)-EGCG is unstable under physiologic conditions and has poor bioavailability. Previously, in an attempt to increase the stability of (–)-EGCG, we introduced peracetate protections to its reactive hydroxyl groups and showed that this peracetate-protected (–)-EGCG [Pro-EGCG (1); formerly named compound 1] could be converted into (–)-EGCG under cell-free conditions. In the current study, we provide evidence that when cultured human breast cancer MDA-MB-231 cells were treated with Pro-EGCG (1), (–)-EGCG was not only converted but also accumulated, accompanied by enhanced levels of proteasome inhibition, growth suppression, and apoptosis induction, compared with cells treated with natural (–)-EGCG. To investigate the potential use of Pro-EGCG (1) as a novel prodrug that converts to a cellular proteasome inhibitor and anticancer agent in vivo, MDA-MB-231 tumors were induced in nude mice, followed by treatment with Pro-EGCG (1) or (–)-EGCG for 31 days. Results of this in vivo study showed a significant inhibition of breast tumor growth by Pro-EGCG (1), compared with (–)-EGCG, associated with increased proteasome inhibition and apoptosis induction in tumor tissues. In conclusion, we have shown that Pro-EGCG (1) increases the bioavailability, stability, and proteasome-inhibitory and anticancer activities of (–)-EGCG in human breast cancer cells and tumors, suggesting its potential use for cancer prevention and treatment. [Cancer Res 2007;67(9):4303–10]

This article has been cited by other articles:

				V. Milacic, S. Banerjee, K. R. Landis-Piwowar, F. H. Sarkar, A. P.N. Majumdar, and Q. P. Dou Curcumin Inhibits the Proteasome Activity in Human Colon Cancer Cells In vitro and In vivo Cancer Res., September 15, 2008; 68(18): 7283 - 7292. [Abstract] [Full Text] [PDF]

				F.-M. Lin, C.-H. Tsai, Y.-C. Yang, W.-C. Tu, L.-R. Chen, Y.-S. Liang, S.-Y. Wang, L.-F. Shyur, S.-C. Chien, T.-L. Cha, et al. A Novel Diterpene Suppresses CWR22Rv1 Tumor Growth In vivo through Antiproliferation and Proapoptosis Cancer Res., August 15, 2008; 68(16): 6634 - 6642. [Abstract] [Full Text] [PDF]